Navigation Links
Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop

Dr. Bill Poland Will Present on the Strategic Use of Incorporating Adherence Data into Clinical Trial Predictions of Antiviral Therapies

MOUNTAIN VIEW, Calif., April 30 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Bill Poland, Ph.D., vice president and lead scientist, Strategic Consulting Services, has been invited to present at a Drug Information Association (DIA) workshop on using patient adherence data at the University of California Washington Center in Washington, DC. Dr. Poland will present on May 6, 2008, joining other leading experts from the pharmaceutical industry and academia in a session on the utility of incorporating adherence estimates in the design of clinical trials intended to learn about exposure-response relationships.

The workshop will provide a forum for scientific discussion and collaborative exchange on opportunities for the use of new methods in the conduct and interpretation of clinical trials through the use of reliable patient adherence data. Dr. Poland's presentation, entitled "Incorporating Adherence into Antiviral Clinical Trial Predictions", will describe how quantitative models of patient compliance for new antiviral agents can be linked with predictive drug-disease models to optimize dosing strategies and support clinical trial simulations. Further information can be found at

"Antiviral drugs present special therapeutic challenges to development teams, including patient compliance with long-term treatment regimens," said Shawn O'Connor, president, CEO and chairman of Pharsight. "To support planning and quantitative decision-making for antiviral development, it is important to account for highly variable patient compliance in the complexities of viral dynamics modeling. Model-based approaches can lead to enhanced clinical trial designs and in developing strategies to optimize tradeoffs such as that between patient compliance and dosing regimen, as well as inform better clinical program investment decisions. Pharsight is pleased to present at this important adherence workshop and to continue its contributions at DIA events, where we look forward to sharing our experience with industry colleagues and interacting with fellow practitioners of modeling and simulation."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight Strengthens Senior Management Team
2. Pharsight Announces Fiscal Fourth Quarter 2008 and Year End Earnings Release Date and Conference Call
3. Pharsight Signs New Diabetes Meta-Database Customer
4. Pharsight to Present at eClinical Forum
5. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
6. FDA and Pharsight Continue to Collaborate Under CRADA
7. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
8. Pharsight Achieves $7.3 Million in Quarterly Revenue
9. Pharsight Expands Global Consulting Services Teams
10. Pharsight to Host European Software Conference
11. Pharsight Files Application for Nasdaq Capital Market Listing
Post Your Comments:
(Date:12/1/2015)... ... December 02, 2015 , ... ... events and association with initiation of treatment for osteoporosis ”. , As corresponding ... pharmacological treatment in patients diagnosed with osteoporosis. Based on a large US managed ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article published ... discrimination claim against the U.S. Department of Health and Human Services, claiming that any ... plans are breaking the clause in the law prohibiting the denial of coverage for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of ... has been named by MedEsthetics magazine as the Best Single Physician Practice in the ... the many elite aesthetic physicians honored by the industry publication. , Dr. Vitenas ...
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015 Array BioPharma ... that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The ... conference through a webcast on the Array ... , --> , ...
(Date:12/1/2015)... Dec. 1, 2015 Assurex Health, Inc. ... test giving healthcare providers an expanded range of ... patients suffering from depression, anxiety, bipolar disorder, posttraumatic ... conditions. i .   ... With the addition of two new drug classes, ...
(Date:12/1/2015)... 1, 2015 --> ... report "Nucleic Acid Labeling Market by Product (Reagents & ... Primer, In Vitro Transcription, Reverse Transcription, End Labeling), by ... The global market is expected to reach USD 1,925.7 ... growing at a CAGR of 8.65%. Browse ...
Breaking Medicine Technology: